- Oops!Something went wrong.Please try again later.
DGAP-News: ABIVAX / Key word(s): Study results
Abivax's phase 1/2 clinical study results of ABX196 in liver cancer show good tolerability and promising signals of clinical benefit and were selected for presentation at the ASCO GI Cancers Symposium 2022
PARIS, France, November 30, 2021 - 6:00 pm (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today reports the good tolerability and promising signals of clinical benefit resulting from its clinical phase 1/2 study conducted with ABX196. In this study, heavily pre-treated hepatocellular cancer (HCC) patients were administered ABX196 in combination with checkpoint inhibitor nivolumab, including patients who were previously exposed to checkpoint inhibitor treatments. These results support the further clinical development of ABX196 in the HCC setting.
The Company further announces today that the dose escalation results of this phase 1/2 study with ABX196 have been selected for a presentation at the renowned ASCO Gastrointestinal Cancers Symposium, taking place on January 20-22, 2022, in San Francisco, CA, USA. The ASCO GI Cancers Symposium is one of the most important international conferences to present and discuss the latest, most innovative and promising research advances in the field of gastrointestinal cancer. It is organized every year by the American Society of Clinical Oncology (ASCO), the world's leading organization in cancer research.
Darren Sigal, M.D., Program Director of GI Oncology at Scripps MD Anderson Cancer Center in San Diego, physician with Scripps Clinic and principal investigator of the study said: "We are excited to observe a good safety profile as well as signals of clinical benefit in liver cancer patients treated with a combination of ABX196 and the checkpoint inhibitor nivolumab. The selection of the results of this phase 1/2 trial for a poster presentation at the ASCO GI Cancers Symposium 2022 validates these first promising data generated in the dose escalation phase of the study. ABX196 is the first non-checkpoint inhibitor immune therapy to be evaluated in HCC, activating the iNKT cell, a key anti-cancer immune cell. We are very much looking forward to present and discuss these results with the world's leading oncology experts at the ASCO GI Cancers Symposium."
According to the embargo policy of ASCO, the detailed clinical data and conclusions of the abstract will be published as of January 18, 2022. Abivax will make the clinical study results publicly available as soon as the embargo has been officially lifted.
A phase 1/2 study of ABX196 in combination with checkpoint inhibitor nivolumab in patients with previously treated hepatocellular carcinoma
Based on the first outcome, the Company is currently assessing next steps for the future clinical development of ABX196 in HCC, also considering the availability of the required financing or the opportunity of a licensing agreement.
About Abivax (www.abivax.com)
This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although the Company believes that its forward-looking statements, forecasts and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors that have been deemed reasonable, such forward-looking statements, forecasts and estimates are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in such forward-looking statements, forecasts and estimates. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document d'Enregistrement Universel). Special consideration should be given to the potential hurtles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and ethics committees of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC, clinical data, Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law.
30.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.